Literature DB >> 17200354

Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors.

Yu Takahashi1, Yuri Akishima-Fukasawa, Noritoshi Kobayashi, Tsuyoshi Sano, Tomoo Kosuge, Yuji Nimura, Yae Kanai, Nobuyoshi Hiraoka.   

Abstract

PURPOSE: It is difficult to predict the biological behavior of pancreatic endocrine tumors (PETs). Our aim was to evaluate the prognostic significance of certain variables in PETs. EXPERIMENTAL
DESIGN: The following variables were examined in 37 patients with PETs and then compared with other clinicopathologic characteristics: histologic tumor structure; microvessel density (MVD) measured by three different methods, including a unique method involving calculation of solid area MVD; endothelial proliferation; and the immunohistochemical expression of vascular endothelial growth factor-A and CXC chemokine CXCL-12. Intratumoral vascular structures were analyzed by double immunofluorescence using 30-microm-thick sections.
RESULTS: The presence of focal and intensive solid growth of tumor cells (large solid nests; P = 0.003), low solid area MVD (P = 0.002), a high endothelial cell proliferation index (EPI; P = 0.005), and high expression of CXCL-12 in PET cells (P = 0.018) were significant unfavorable prognostic indicators. The predominant structure of the overall tumor histology and the expression of vascular endothelial growth factor-A did not separate aggressive PETs. In areas of focal solid growth, tumor-associated blood vessels had obviously low MVD and high EPI, and their structures were poorly formed with highly abnormal features, in comparison with other areas. High expression of CXCL-12 in tumor cells was significantly associated with variables representing tumor growth, hematogenous tumor spread, low MVD, high EPI, and the presence of large solid nests.
CONCLUSIONS: This study has provided novel findings on the prognostic features of tumor architecture and tumor-associated angiogenesis in PETs. CXCL-12 is the first candidate molecule in association with neoangiogenesis in PETs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200354     DOI: 10.1158/1078-0432.CCR-06-1408

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  Xenon-inhalation computed tomography for noninvasive quantitative measurement of tissue blood flow in pancreatic tumor.

Authors:  Masaru Kubota; Takamichi Murakami; Hiroaki Nagano; Hidetoshi Eguchi; Shigeru Marubashi; Shogo Kobayashi; Hiroshi Wada; Masahiro Tanemura; Keizo Dono; Shoji Nakamori; Masato Sakon; Morito Monden; Masaki Mori; Yuichiro Doki
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

Review 2.  Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

Authors:  Diana Martins; Francesca Spada; Ioana Lambrescu; Manila Rubino; Chiara Cella; Bianca Gibelli; Chiara Grana; Dario Ribero; Emilio Bertani; Davide Ravizza; Guido Bonomo; Luigi Funicelli; Eleonora Pisa; Dario Zerini; Nicola Fazio
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.493

3.  Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.

Authors:  Kazuhiko Kasuya; Yuichi Nagakawa; Minako Suzuki; Yoshiaki Suzuki; Bunso Kyo; Satoru Suzuki; Takaaki Matsudo; Takao Itoi; Akihiko Tsuchida; Tatsuya Aoki
Journal:  Exp Ther Med       Date:  2012-01-18       Impact factor: 2.447

4.  Angiopoietin-1 gene-modified human mesenchymal stem cells promote angiogenesis and reduce acute pancreatitis in rats.

Authors:  Jie Hua; Zhi-Gang He; Dao-Hai Qian; Sheng-Ping Lin; Jian Gong; Hong-Bo Meng; Ting-Song Yang; Wei Sun; Bin Xu; Bo Zhou; Zhen-Shun Song
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Three-dimensional reconstruction of neovasculature in solid tumors and basement membrane matrix using ex vivo X-ray microcomputed tomography.

Authors:  Seunghyung Lee; Mary F Barbe; Rosario Scalia; Lawrence E Goldfinger
Journal:  Microcirculation       Date:  2014-02       Impact factor: 2.628

6.  Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.

Authors:  E Belousova; G Karmazanovsky; A Kriger; D Kalinin; L Mannelli; A Glotov; N Karelskaya; O Paklina; A Kaldarov
Journal:  Clin Radiol       Date:  2016-11-24       Impact factor: 2.350

7.  Letter regarding "Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase".

Authors:  Shuai Ren; Zhongqiu Wang
Journal:  Abdom Radiol (NY)       Date:  2020-10-16

8.  Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Ming-Huang Chen; Yi-Chen Yeh; Yi-Ming Shyr; Yi-Hua Jan; Yee Chao; Chung-Pin Li; Shin-E Wang; Cheng-Hwai Tzeng; Peter Mu-Hsin Chang; Chun-Yu Liu; Ming-Han Chen; Michael Hsiao; Chi-Ying F Huang
Journal:  J Gastroenterol       Date:  2012-06-16       Impact factor: 7.527

9.  Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation.

Authors:  N Hiraoka; Y Ino; S Sekine; H Tsuda; K Shimada; T Kosuge; J Zavada; M Yoshida; K Yamada; T Koyama; Y Kanai
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

10.  Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.

Authors:  Dong Wook Kim; Hyoung Jung Kim; Kyung Won Kim; Jae Ho Byun; So Yeon Kim; Ki Byung Song; Nikhil H Ramaiya; Sree Harsha Tirumani; Seung-Mo Hong
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.